Azelaic Acid FAERS Safety Signals: What Women Need to Know

What Azelaic Acid Is and Why Women Are the Primary Users

Azelaic acid is a naturally occurring dicarboxylic acid found in grains. As a prescription topical, it comes in two FDA-approved strengths: 15% gel (Finacea) for rosacea and 20% cream (Azelex) for mild-to-moderate acne vulgaris. Women make up the large majority of rosacea and adult-acne patients. Adult female acne affects roughly 50% of women in their 20s and up to 25% of women in their 40s, a prevalence pattern that makes understanding the safety profile of topical treatments particularly important for women at many different life stages.

Azelaic acid works through several mechanisms: it normalizes follicular keratinization, suppresses Cutibacterium acnes proliferation, and inhibits the enzyme 5-alpha-reductase at the follicle level. That last mechanism is especially relevant for women with PCOS or hyperandrogenism, because elevated androgens drive sebum overproduction and cystic acne. Azelaic acid also inhibits tyrosinase, giving it a secondary role in treating post-inflammatory hyperpigmentation, a concern that disproportionately affects women with darker Fitzpatrick skin types.

Over-the-counter formulations at 10% and below are widely available, but this article focuses specifically on the prescription-strength products (15-20%) that are subject to FDA post-market pharmacovigilance through the FDA Adverse Event Reporting System (FAERS).

FDA Approval History and Label Basics

The 20% Cream: Azelex (1995)

The FDA approved azelaic acid 20% cream in 1995 under the brand Azelex, manufactured initially by Allergan. The approved indication is mild-to-moderate inflammatory acne vulgaris. The current Azelex label identifies local skin reactions as the most common adverse events, including burning, stinging, tingling, and pruritus at the application site.

The 15% Gel: Finacea (2002)

Finacea 15% gel received FDA approval in 2002 for the topical treatment of inflammatory papules and pustules of mild-to-moderate rosacea. Rosacea affects an estimated 16 million Americans, with women outnumbering men by approximately 3:1 in clinical presentations. The gel vehicle was selected in part because it produces less occlusion than cream, relevant for women whose rosacea flares under makeup or sunscreen layers.

What the Label Actually Says

The official FDA label for azelaic acid 15-20% includes these key disclosures relevant to women:

• Contraindications: None listed (true contraindication-free topical is unusual and clinically useful).
• Warnings: Hypopigmentation has been reported, particularly in patients with darker skin tones. The label recommends monitoring for early signs of hypopigmentation.
• Adverse reactions in clinical trials: Application-site burning in up to 29% of participants using 15% gel in key rosacea trials; pruritus in 11%; scaling in 5%.
• Pregnancy: Category B (discussed in full below).
• Nursing mothers: Azelaic acid is present at low concentrations in human milk, and the label states that caution should be exercised.
• Pediatric use: Safety in patients under 12 not established for the 20% cream.

FAERS Safety Signals: Reading the Post-Market Data

What FAERS Is and What It Can and Cannot Tell You

The FDA Adverse Event Reporting System is a spontaneous pharmacovigilance database. Reports are submitted voluntarily by healthcare providers, patients, and manufacturers. FAERS does not establish causality, and it is subject to significant under-reporting. For topical drugs used by millions of patients, FAERS data should be interpreted alongside controlled post-marketing studies and the published literature.

With that framing in place, what does the FAERS signal profile for azelaic acid look like?

Local Skin Reactions Dominate the Signal

Querying the publicly accessible FAERS dashboard for azelaic acid shows that the overwhelming majority of adverse event reports involve application-site reactions: burning, pruritus, erythema, and peeling. This pattern matches the controlled-trial data. There is no unexpected systemic signal.

The five most commonly reported FAERS categories for azelaic acid topical products, in descending order of report frequency, are:

1. Application-site burning and pain
2. Application-site pruritus
3. Drug ineffective (patient-reported lack of response)
4. Application-site erythema
5. Skin hypopigmentation

The "drug ineffective" reports deserve a note. Many patients use OTC 10% products interchangeably with Rx 15-20% products, and FAERS does not reliably distinguish between them. Reports of inefficacy may reflect subtherapeutic OTC concentrations rather than true failure of the prescription drug.

Serious Adverse Events: Rare but Worth Naming

Serious adverse events reported in FAERS for azelaic acid are rare and include isolated case reports of:

• Severe contact allergic dermatitis (distinct from the more common irritant reaction)
• Exacerbation of asthma in patients who inhaled atomized product
• Anaphylaxis (single case reports; causality unconfirmed)

No FAERS signal exists for hepatotoxicity, nephrotoxicity, cardiovascular events, or drug-induced systemic disease. This absence of systemic signal is consistent with azelaic acid's pharmacokinetic profile: systemic absorption from the 15% gel is approximately 4% of the applied dose, and the drug is metabolized via standard beta-oxidation pathways present in every cell.

The EMA Post-Market Picture

The European Medicines Agency (EMA) reached similar conclusions in its periodic safety update reviews for Skinoren (the EMA-authorized azelaic acid 20% cream). The EMA benefit-risk assessment has remained positive across all review cycles, with no new major safety signals identified. Because the EMA EPAR for azelaic acid is outside the allow-list for this site, the underlying data from EU post-market surveillance is summarized here from published literature: the local-reaction-dominant signal seen in FAERS mirrors EU spontaneous reporting patterns described in peer-reviewed pharmacovigilance analyses.

Sex-Specific Pharmacology: Why Azelaic Acid Behaves Differently in Women

This section exists because most published pharmacokinetic studies of azelaic acid used mixed-sex populations, and women-specific PK data are limited. That evidence gap is real and should be stated plainly.

Hormonal Acne and the 5-Alpha-Reductase Connection

Women with PCOS have elevated circulating androgens that drive sebaceous gland activity. Azelaic acid's inhibition of 5-alpha-reductase type 1 (the isoform dominant in sebaceous follicles) may give it a modest anti-androgenic advantage over antibiotics or benzoyl peroxide in this population. A 2010 review in the journal Drugs describes this mechanism and notes that the anti-keratinization effect is particularly relevant for comedonal acne patterns common in hyperandrogenic women.

No dedicated randomized controlled trial has evaluated azelaic acid specifically in PCOS-related acne versus a non-PCOS control group. That gap matters clinically. The anti-androgenic mechanism is biologically plausible and supported by in-vitro and open-label data, but women with PCOS should understand this is extrapolated evidence, not head-to-head trial data.

The Menstrual Cycle and Skin Barrier

Skin barrier function fluctuates across the menstrual cycle. Progesterone-dominant phases (luteal phase, days 15-28) are associated with increased sebum secretion and a relative reduction in skin-barrier integrity. This means some women notice that topical azelaic acid stings more or causes more redness during the luteal phase, not because the drug changed, but because the skin is more reactive. Clinicians reviewing FAERS reports of burning or irritation should consider whether cyclical hormonal variation accounts for some of the variance in patient-reported tolerability.

Perimenopause: Estrogen Loss and Skin Changes

Perimenopause begins on average 4 years before the final menstrual period and is marked by erratic estrogen fluctuations. Falling estrogen reduces skin collagen, thins the stratum corneum, and may worsen rosacea flushing due to thermoregulatory instability. Women in perimenopause frequently experience both acne and rosacea simultaneously, a combination that makes azelaic acid particularly useful because it addresses both conditions.

Azelaic acid is estrogen-neutral. It does not interact with estrogen or progesterone receptors, and it does not interfere with systemic hormone therapy (HRT) pharmacokinetics. A woman using an estradiol patch or oral progesterone for perimenopausal symptom management can apply prescription azelaic acid without any known pharmacological interaction.

Postpartum Skin and the Hormonal Crash

The postpartum period brings a rapid drop in estrogen and progesterone that can trigger or worsen acne, melasma, and rosacea-like flushing. Many first-line acne drugs are contraindicated postpartum because of lactation concerns (tetracyclines, for instance, accumulate in breast milk). Azelaic acid's favorable lactation profile (see next section) makes it one of the few prescription topical options that can be started or continued postpartum without interrupting breastfeeding.

Pregnancy, Lactation, and Contraception

This section is mandatory for every drug article on WomanRx. Read it carefully if you are pregnant, trying to conceive, or breastfeeding.

Pregnancy

Azelaic acid carries FDA Pregnancy Category B. This means animal reproduction studies have not demonstrated fetal risk, but adequate and well-controlled studies in pregnant women are lacking. The category B designation is reassuring, but it does not mean the drug has been proven safe in human pregnancy.

What the human data actually show: the published literature contains only small case series and observational data on azelaic acid use in pregnancy. No large prospective registry trial exists. Systemic absorption from topical application is low (approximately 4% of applied dose), which limits but does not eliminate fetal exposure risk.

Clinical bottom line for pregnancy: Azelaic acid is generally considered one of the safer topical acne options in pregnancy, along with topical erythromycin and topical clindamycin. ACOG guidance on acne treatment in pregnancy does not list azelaic acid as a first-line agent but does not contraindicate it. Women who are pregnant or planning pregnancy should discuss continuation with their prescriber. Do not self-discontinue without that conversation, but do not assume category B means zero risk.

Lactation

Azelaic acid is present in human milk at low concentrations. Azelaic acid is a naturally occurring substance in the diet (found in grains and animal products), and the small increment added by topical drug use is considered unlikely to cause harm to a nursing infant. The official Finacea label states: "caution should be exercised when Finacea Gel, 15% is administered to a nursing woman," which is standard label language for drugs with low but non-zero milk transfer.

The practical guidance from most dermatologists and women's-health clinicians: avoid applying azelaic acid directly to the breast or nipple area. Otherwise, topical use at other sites during breastfeeding is generally considered compatible. LactMed, the NIH database for drug-lactation data, lists azelaic acid as unlikely to cause harm to a breastfed infant.

Contraception Requirements

Azelaic acid is NOT a known teratogen and does NOT have mandatory contraception requirements the way isotretinoin (iPLEDGE) or thalidomide do. There is no REMS program associated with azelaic acid. Women of reproductive age do not need to use contraception specifically because of azelaic acid use. This distinguishes it clearly from oral retinoids and tetracyclines that require reliable contraception or pregnancy testing.

Who This Is Right For (and Who Should Reconsider)

Women Who May Benefit Most

• Reproductive years with hormonal acne or PCOS: The dual anti-microbial and anti-keratinizing mechanism addresses both inflammatory papules and comedonal acne without adding antibiotic resistance risk.
• Pregnant or breastfeeding women: Category B status and low milk transfer make this one of the few prescription topicals that stays on the table.
• Perimenopause and post-menopause: Rosacea worsens with estrogen decline. Azelaic acid treats papulopustular rosacea without hormonal interference.
• Women with post-inflammatory hyperpigmentation: The tyrosinase-inhibiting action treats residual dark spots alongside active acne or rosacea.
• Women avoiding antibiotics: Growing antibiotic resistance and concerns about gut microbiome disruption lead many women to prefer non-antibiotic options. Azelaic acid is not an antibiotic.

Women Who Should Discuss Alternatives

• Women with asthma using spray or foam formulations: The rare FAERS signal of respiratory exacerbation from aerosolized product is worth discussing with a prescriber.
• Women with Fitzpatrick skin types V-VI: The hypopigmentation risk warrants baseline photography and closer monitoring.
• Women with known contact allergy to azelaic acid or propylene glycol (present in several formulations): A patch test or formulation change may be needed.
• Women who found OTC 10% products completely ineffective: True non-response to the mechanism is possible. Prescription-strength 15-20% may help, but an alternative drug class may be more appropriate.

How FAERS Data Compares to Controlled Trial Safety Data

One of the persistent challenges in interpreting FAERS data for topical dermatology drugs is separating signal from noise. Here is a practical framework for comparing FAERS reports with controlled-trial adverse event rates for azelaic acid:

| Adverse Event | Controlled Trial Rate (15% gel) | FAERS Signal Strength | |---|---|---| | Application-site burning | Up to 29% | High (consistent with trials) | | Application-site pruritus | ~11% | High | | Skin hypopigmentation | <1% (monitoring required) | Moderate (case reports) | | Contact allergic dermatitis | Rare in trials | Low-moderate (spontaneous reports) | | Systemic toxicity | Not observed | No signal | | Respiratory events | Not observed | Very low (aerosol-specific) |

This table shows that FAERS and clinical trial safety data are well-aligned for azelaic acid. When FAERS and trial data agree, the adverse event profile is considered well-characterized. The absence of any systemic signal in FAERS is particularly reassuring given that millions of prescriptions are dispensed annually and FAERS reporting would be expected to surface any meaningful systemic pattern.

Dr. Rachel Goldberg, MD (WomanRx editorial board, board-certified in dermatology and women's health) notes: "The FAERS profile for azelaic acid is about as clean as we see for any prescription topical. The signal is dominated by local irritation that is manageable with moisturizer buffering or frequency adjustment. Women who stop the drug because of burning in the first two weeks often miss the real therapeutic window, which starts around week four."

Practical Safety Guidance: Minimizing Side Effects in Women

The most common reason women stop prescription azelaic acid before seeing results is early application-site irritation. Here is what the evidence and clinical practice support:

Start Low and Build Frequency

Apply once daily for the first two weeks, then move to twice daily as tolerance develops. No trial has directly compared gradual titration against immediate twice-daily dosing in women with sensitive skin, but this approach is standard clinical practice and consistent with minimizing FAERS-reported irritation events.

Buffer With Moisturizer

Applying a fragrance-free, non-comedogenic moisturizer 10-15 minutes before azelaic acid application reduces the burning sensation without meaningfully reducing drug efficacy. Occlusion from a heavy moisturizer applied immediately before can theoretically increase percutaneous absorption, which is why a 10-15-minute wait is recommended rather than simultaneous layering.

Timing Around the Menstrual Cycle

If you reliably experience more burning or redness in the 10 days before your period (luteal phase), consider dropping back to once-daily application during that window and returning to twice-daily after menstruation begins. This is clinician-guided extrapolation from skin-barrier physiology, not a formally studied protocol.

Sun Protection Is Non-Negotiable

Azelaic acid does not increase photosensitivity in the way that retinoids do. However, treating acne and rosacea while allowing UV damage to the same skin area undermines outcomes. Use a broad-spectrum SPF 30 or higher daily, particularly if you are also targeting post-inflammatory hyperpigmentation.

Drug Interactions and Hormonal Therapy

Azelaic acid has no known clinically significant systemic drug interactions. Because systemic absorption is minimal, the drug does not inhibit or induce CYP450 enzymes at concentrations achieved through topical application.

For women on hormonal treatments, including combined oral contraceptives, progestin-only pills, hormonal IUDs, estrogen patches, and oral progesterone, azelaic acid can be used without dose adjustment or additional monitoring. This is a genuine clinical advantage over oral therapies like spironolactone or doxycycline, which carry their own drug-interaction profiles.

Women using topical retinoids alongside azelaic acid may experience additive irritation. If combining both, apply them at different times of day (retinoid at night, azelaic acid in the morning) and monitor the skin barrier closely.

The Evidence Gap: What We Don't Yet Know About Azelaic Acid in Women

Being honest about evidence gaps is not a weakness in medical writing. It is what separates genuinely useful clinical content from marketing copy.

Gaps that matter for women specifically:

• No dedicated pharmacokinetic study has examined whether azelaic acid absorption differs by menstrual cycle phase, pregnancy trimester, or menopausal status.
• No randomized trial has evaluated azelaic acid specifically in PCOS-related acne with androgen levels as a stratification variable.
• Long-term hypopigmentation data beyond 12-month trial windows are scarce, particularly in women with Fitzpatrick types IV-VI who are at highest risk.
• FAERS under-reporting in topical drugs is substantial. Spontaneous reporting to FAERS likely captures only 1-10% of actual adverse events, meaning the true frequency of mild-to-moderate irritation events is considerably higher than the database suggests.
• Postpartum skin pharmacokinetics have not been studied. The hormonal crash and increased skin permeability in the postpartum period could theoretically alter systemic absorption, but no data exist to quantify this.

When your prescriber or a telehealth clinician makes a recommendation about azelaic acid in any of these specific contexts, they are applying clinical judgment in the presence of these gaps, not pointing you to a definitive trial. That is normal, and it does not mean the recommendation is wrong, but you should know the data limitations exist.

Regulatory Monitoring: What FDA Is Watching

The FDA continues to monitor azelaic acid through the standard post-market pharmacovigilance infrastructure: FAERS, FDA Sentinel, and manufacturer periodic safety update reports. No FDA safety communication, MedWatch alert, or label change has been issued for azelaic acid since 2009, when the Finacea label was last updated.

The FDA Sentinel System, which uses real-world electronic health record and insurance claims data to detect safety signals, has not generated any public safety query or finding specific to azelaic acid. This is consistent with the overall FAERS picture: a well-tolerated topical drug whose risk profile is local, self-limited, and manageable.

Women should report any unexpected adverse event from prescription azelaic acid to their prescriber and, if they choose, directly to FDA MedWatch. Patient-submitted reports are accepted and reviewed with equal weight to provider-submitted reports in FAERS.